This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

This study has been completed.
Information provided by:
CSL Behring Identifier:
First received: September 12, 2005
Last updated: March 11, 2015
Last verified: February 2011
HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provide clinically relevant data on dosing, efficacy and safety in subjects with HAE.

Condition Intervention Phase
Hereditary Angioedema Biological: C1 Esterase Inhibitor Biological: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks

Resource links provided by NLM:

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • Time to Start of Relief of Symptoms From HAE Attack [ Time Frame: Up to 24 h after start of study treatment ]
    The start of symptom relief was determined by subject self-assessment. Time to start of symptom relief was set to 24 hours if the subject received rescue medication (blinded study medication, narcotic analgesics, antiemetics, open-label C1-INH, or fresh frozen plasma) at any time point after the start of study treatment but before start of relief.

Secondary Outcome Measures:
  • Number of Subjects With Worsened Intensity of Clinical HAE Symptoms [ Time Frame: Baseline and between 2 and 4 h after start of study treatment ]
    Includes any worsening of intensity of at least 1 of the HAE symptoms present at baseline. Routinely checked symptoms included pain, nausea, vomiting, cramps, and diarrhea.

  • Number of Vomiting Episodes [ Time Frame: Within 4 h after start of study treatment ]

Other Outcome Measures:
  • Time to Complete Resolution of All HAE Symptoms, Including Pain [ Time Frame: Up to 24 h after start of study treatment ]
    Complete resolution of symptoms was determined by subject self-assessment.

  • Number of Subjects Receiving Rescue Study Medication [ Time Frame: Within 4 h after start of study treatment ]

Enrollment: 126
Study Start Date: June 2005
Study Completion Date: December 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: C1-INH 10 U/kg bw
10 Units (U)/kg body weight (bw) dose
Biological: C1 Esterase Inhibitor
Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
Other Names:
  • Berinert
  • Berinert P
  • CE1145
Experimental: C1-INH 20 U/kg bw
20 U/kg bw dose
Biological: C1 Esterase Inhibitor
Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
Other Names:
  • Berinert
  • Berinert P
  • CE1145
Placebo Comparator: Placebo Biological: Placebo
Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
Other Name: Physiological saline solution

Detailed Description:

For each subject, only a single abdominal or facial attack was treated and evaluated. After receiving treatment, subjects were observed for a minimum of 4 hours, after which they could be discharged from the study center if they reported onset of symptom relief. Starting from 4 hours after treatment, subjects who reported insufficient or no symptom relief could receive a second dose of double-blind treatment (called "rescue medication") as follows: C1-INH 20 U/kg bw for subjects initially receiving placebo, C1-INH 10 U/kg bw for subjects initially receiving C1-INH 10 U/kg bw, and placebo for subjects initially receiving C1-INH 20 U/kg bw.

The study was defined to be successful if the primary outcome measure and at least one of the secondary outcome measures were met in the comparison between the C1-INH 20 U/kg bw group and the Placebo group.


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Documented congenital C1-INH deficiency
  • Acute facial or abdominal HAE attack

Key Exclusion Criteria:

  • Acquired angioedema
  • Treatment with any other investigational drug within the last 30 days before study entry
  • Treatment with any C1-INH concentrate within the previous 7 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00168103

  Hide Study Locations
United States, California
Study Site
Granada Hills, California, United States, 91344
United States, Florida
Study Site
Weston, Florida, United States, 33331
United States, Georgia
Study Site
Atlanta, Georgia, United States, 30342
United States, Idaho
Study Site
Idaho Falls, Idaho, United States, 83404
United States, Illinois
Study Site
Chicago, Illinois, United States, 60612
United States, Louisiana
Study Site
Shreveport, Louisiana, United States, 71130
United States, Massachusetts
Study Site
Boston, Massachusetts, United States, 02115
United States, Minnesota
Study Site
Plymouth, Minnesota, United States, 55411
United States, Nebraska
Study Site
Omaha, Nebraska, United States, 68131
United States, New York
Study Site
Bronx, New York, United States, 10461
United States, Ohio
Study Site
Cincinnati, Ohio, United States, 45231
United States, Oklahoma
Study Site
Tulsa, Oklahoma, United States, 74133
United States, Oregon
Study Site
Eugene, Oregon, United States, 97401
United States, Pennsylvania
Study Site
Hershey, Pennsylvania, United States, 17033
United States, South Dakota
Study Site
Rapid City, South Dakota, United States, 57702
United States, Texas
Study Site
Dallas, Texas, United States, 75230
United States, Washington
Study Site
Bellingham, Washington, United States, 98225
Study Site
Buenos Aires, Argentina
Study Site
Westmead, Australia
Study Site
Plovdiv, Bulgaria
Study Site
Sofia, Bulgaria
Study Site
Edmonton, Canada
Study Site
Ottawa, Canada
Czech Republic
Study Site
Brno, Czech Republic
Study Site
Budapest, Hungary
Study Site
Tel Hashomer, Israel
Macedonia, The Former Yugoslav Republic of
Study Site
Skopje, Macedonia, The Former Yugoslav Republic of
Study Site
Grodzisk Mazowiecki, Poland
Study Site
Krakow, Poland
Study Site
Tirgu-Mures, Romania
Russian Federation
Study Site 1
Moscow, Russian Federation
Study Site 2
Moscow, Russian Federation
Study Site 3
Moscow, Russian Federation
Study Site
Madrid, Spain
Study Site
Goeteborg, Sweden
United Kingdom
Study Site
London, United Kingdom
Sponsors and Collaborators
CSL Behring
Study Director: Program Director, Clinical R&D CSL Behring
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Global Head Clinical Research & Development, CSL Behring Identifier: NCT00168103     History of Changes
Other Study ID Numbers: CE1145_3001
2004-001186-17 ( EudraCT Number )
Study First Received: September 12, 2005
Results First Received: April 21, 2010
Last Updated: March 11, 2015

Keywords provided by CSL Behring:
C1 Inhibitor
Hereditary angioedema
Acute HAE attack

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Complement C1s
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Immunologic Factors
Physiological Effects of Drugs
Complement Inactivating Agents
Immunosuppressive Agents processed this record on August 17, 2017